In-Body cancer killers: new CAR-T therapy targets Hard-to-Treat blood cancers
NCT ID NCT07586709
First seen May 25, 2026 · Last updated May 25, 2026
Summary
This early-stage study tests the safety of a new type of immunotherapy for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. Instead of modifying cells in a lab, the treatment creates cancer-fighting CAR-T cells directly inside the body, targeting two proteins (BCMA and GPRC5D) on the cancer cells. The study will enroll 18 participants and closely monitor side effects like cytokine release syndrome and nerve toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.